Get started

Growth-stocks

Nykaa - Strong Growth Cup & Handle with Detailed fundamentalsFSN E-Commerce Ventures Limited (Nykaa) – Technical & Fundamental Analysis Company Overview: FSN E-Commerce Ventures Limited (Nykaa) is a digitally native consumer technology platform, delivering a content-led, lifestyle retail experience. Since its incorporation in 2012, the company has focused on designing a differentiated brand discovery journey for its consumers. It offers a diverse portfolio of beauty, personal care, and fashion products, including owned-brand products manufactured in-house. Nykaa provides an omnichannel experience to cater to consumer preferences and convenience. Technical Analysis Chart Patterns: Cup and handle breakout; Today 1-hour parallel channel breakout Current Market Price (CMP): ₹260 Targets: ₹301, ₹350 Support Levels: ₹230, ₹195 Recent News & Highlights ✅Q1 FY26 Results: Consolidated net profit surged 142% YoY to ₹23.30 Cr; revenue up 23.4% to ₹2,155 Cr ✅Arbitration Win: Nykaa Fashion received ₹10 Cr compensation from arbitration award Q1 FY26 Guidance: Management anticipates consolidated net revenue growth at lower end of mid-twenties range YoY ✅Fashion Segment Target: Company expects EBITDA breakeven in fashion by FY26 ✅Organic Portfolio Expansion: Aims to increase organic portfolio by 30% annually to reach ₹6,000 Cr GMV ✅Q4 FY25 Performance: EBITDA ₹133 Cr vs ₹93.28 Cr YoY; EBITDA margin improved to 6.47% from 5.59% ✅Corporate Action: NCLT approved merger of Iluminar Media (LBB) into Nykaa Fashion Analytical Summary Operational Excellence: Revenue growth of 24.5% YoY with net profit doubling to ₹66.08 Cr demonstrates strong execution and operating leverage. The company is scaling both beauty and fashion verticals while expanding margins. Capital Structure: Debt increased 41% to ₹961 Cr, but debt-to-equity remains negligible at 0.04, showing conservative leverage. ROE at 5.9% suggests room for improvement in capital efficiency. Valuation Risk: PE of 675.77 and PB of 40.5 reflect aggressive growth expectations. EV/EBITDA of 117.5 leaves minimal margin of safety, requiring caution for long-term investors. SWOT Analysis Strengths (16 Factors): Rising net and operating cash flows for 2 consecutive years Strong EPS growth; quarterly profit margins expanding Improving RoCE, ROE, and ROA Consistent revenue growth for past 2 quarters Clean governance; zero promoter pledge Weaknesses (3 Factors): Promoter shareholding dilution Expensive valuation (PE > 40) limits margin of safety Opportunities (1 Factor): Increasing FII/FPI shareholding validates institutional interest Disclaimer This analysis is for educational and informational purposes only. It does not constitute investment advice. Trading and investing in stocks involve risks, and individuals should conduct their own due diligence or consult with a qualified financial advisor before making any investment decisions. The author is not responsible for any gains or losses arising from the use of this analysis.
NSE:NYKAALong
by Madhumitha_Prabhu
Tamilnad Mercantile Bank (TMB) – Update | 3.5% Move from Our Lvl🟢 Tamilnad Mercantile Bank (TMB) – Update | 3.5% Move from Our Level 🚀 Latest Update : Our analysis shared around ₹499 has played out well — TMB made an intraday high of ₹517, gaining nearly 3.5% from the mentioned level. 🏦 Company Overview: Tamilnad Mercantile Bank Limited is one of the oldest and leading old private sector banks in India. The bank offers a wide range of banking products and services to retail, MSME, agricultural, and corporate customers. Retail Products: Home loans, personal loans, auto loans, educational loans, business loans, and security-backed loans. MSME Portfolio: Loans for manufacturing, traders, and service sector enterprises. Agricultural Loans: Offered to individual farmers, farmer groups, agri-businesses, and agri-corporates. 📊 Technical View: High Reached: ₹517 (▲3.5%) Resistance: ₹510 – price tested and faced mild rejection here. Supports: ₹466 / ₹440 💡 View: The stock showed strong momentum from the support zone and approached its major 1-year resistance area near ₹510–₹515. A sustained close above ₹515 can confirm a breakout and open the next upside targets of ₹535 / ₹600. 📈 For educational purpose only. Not a buy/sell recommendation.
NSE:TMBLong
by Madhumitha_Prabhu
DALBHARATDALBHARAT - The stock is consolidating and trying to break the range. There is no possibility of much decline. As soon as it breaks the range, good momentum can be seen. Hello traders, As always, simple and neat charts so everyone can understand and not make it too complicated. rest details mentioned in the chart. will be posting more such ideas like this. Until that, like share and follow :) check my other ideas to get to know about all the successful trades based on price action. Thanks, Ajay. keep learning and keep earning.
NSE:DALBHARATLong
by AjayDhakad_Keep_it_simple
MEDI ASSIST HEALTH SERVICESMedi Assist Healthcare Services Limited is a health-tech and insurance-tech company that manages health benefits for employers, retail members, and public health schemes, primarily serving insurance companies. Company provides third-party administration (TPA) services to insurance companies through its wholly-owned Subsidiaries, Medi Assist TPA, Medvantage TPA, and Raksha TPA. A third-party administrator is an organization that processes health insurance claims for insurance companies and provides services such as policy administration, customer service, and network management, among others. As of 2023, company collaborated with 35 insurance companies in India and globally. In FY23, company managed a CAGR of 35.67%. The group accounts portfolio as a percentage of revenue from contracts with customers was 72.19% and the retail portfolio was 10.98%. Company also acts as a facilitator between (a) insurance companies and their policyholders, (b) insurance companies and healthcare providers (such as hospitals), and (c) the Government and beneficiaries of public health schemes. Company serviced over 9500 group accounts across sectors to help administer the insurance requirements of their employees. It held a significant share of the total health insurance market for group accounts, representing 26.39% of India’s overall group health insurance market in FY23. Company also services individual insurance policyholders, and for FY23 it managed Rs 17.57 billion of premiums for the retail health insurance market, representing 5.06% of the overall retail health insurance market in India. In H1FY24, company helped settle 3.05 million claims, comprising 1.37 million in-patient claims and 1.68 million domiciliary or out-patient claims. Medi assist also facilitates other healthcare and ancillary services such as hospitalization services, call center services, customer relations and contract management services, billing services, and claims processing services through its Company and other Subsidiaries, IHMS, Mayfair India, Mayfair UK, Mayfair Group Holding, Mayfair Philippines, and Mayfair Singapore. Company has developed a pan-India healthcare provider network, which comprises 18,754 hospitals across 1,069 cities and towns and 31 states (including union territories) in India and a network across 141 countries globally, as of 2023. Company intends to pursue acquisition opportunities to expand its existing service offerings, increase market share in existing markets, and expand to new geographies. In the last eight years, company has completed several acquisitions, including the acquisition of Dedicated Healthcare Services TPA (India), Medicare Insurance TPA Services (India), IHMS, Mayfair India, Medvantage TPA, and Raksha Health Insurance TPA. Financial Performance: - Total premiums under management administered by the company was at Rs. 19,050 crores as of March 31, 2024, showing a growth of 30.7% over the previous year. - Group segment fund was Rs. 16,709 crores, with a growth of 30.4% year-on-year. - Retail segment stood at Rs. 2,341 crores, showing a growth of 33.2% year-on-year. - Company's share of the total health insurance industry premium was at 19.6%, with a growth of 186 basis points over the previous year. Operational Highlights: - Maintained group account retention at 94.7%. - Processed 3.6 million outpatient claims in the last year. - Won an award for "Best use of AI in Healthcare" for the Fraud Detection Engine. - Continuing to invest in preventing fraud, waste, and abuse in the system. - Building a team of data scientists for better data security and analytics. Financials: - Total income for the quarter ended March 31, 2024, was Rs. 171 crores, showing a growth of 23% year-on-year. - EBITDA for the quarter was INR 37 crores, with a margin of 22% on operating revenue. - Profit after tax stood at Rs. 25 crores, showing a growth of 50% year-on-year. - Total income for the year ended March 2024 was Rs. 653 crores, with a growth of 26% over the previous year. - EBITDA for the year was Rs. 133 crores, with a margin of 21% on the operating revenue. - Profit for the period, adjusting for exceptional items, was Rs. 92 crores, showing a growth of 22% year-on-year. Technology and Investment: - Investing around 3-4% of revenues every year in technology. Total investment in the platform and capitalization as of March 31, 2024, was Rs. 10 crores. - Investing in a platform for the UK, with an expected cost of around 8 crores. Future Outlook: - Expecting to bring the acquisitions to the company's margin profile in the next 2-3 quarters. - Focused on enhancing insurer relationships and expanding benefits in the retail segment. - Cashless facility being expanded to non-network hospitals for emergency access. - Strong emphasis on technology for service delivery and customer retention. Challenges and Opportunities: - Opportunities seen in expanding the retail market share and leveraging technology for growth. - Optimistic outlook expressed by the management regarding future prospects and growth potential.
NSE:MEDIASSISTLong
by CannySunny
Buy Mankind Pharma for major upside . 2 lakh to 2 Cr journey Cmp 2300 Buy near 2280 short term target 2408 &2495 Now take a look of Long term journey Mankind Pharma cam be a multibagger counter 5 years Sales, profit and return of equity growth almost more than 20% and this can be increase more and more . Counter going to reach at 1 lakh cr capital this year and after that it will unstoppable . 100% debt free company All the parameter are perfect for long term selection . Just invest 2 lakh in this counter during upcoming 2 years and sleep relax... After 20 years your 2 lakh will become 2 cr. We personally start investing in this counter . If you dont have 2 lakh then you can follow 5000Rs SIP for 40 months You can earn with trading but if you want to create a wealth then long term investing is only solution . Dont miss this opportunity .
NSE:MANKINDLong
by MVLINDIA